pulver til infusionsvæske

DRUG5 trials

Sponsors

Itb-Med AB, Gentofte Hospital, Region Hovedstaden, Hvidovre Hospital, Region Sjaelland, Reponex Pharmaceuticals A/S

Conditions

Community-acquired pneumoniaGram-negative BacteremiaRenal TransplantationStaphylococcus aureus bacteremiaperitonitis

Phase 1

Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients with multi-quadrant peritonitis undergoing abdominal surgery: A randomized placebo-controlled trial (TRIPLE)

Not yet recruitingCTIS2024-520317-49-02

Region Sjaelland, Reponex Pharmaceuticals A/Speritonitis

Target: 32Updated: 2026-01-12

Phase 2

A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients

CompletedCTIS2023-507895-36-00

Itb-Med ABRenal Transplantation

Start: 2021-06-06End: 2024-12-11Target: 33Updated: 2024-08-02

Local Antibiotic Delivery for Community Acquired Pneumonia (LANDCAP 2)

Not yet recruitingCTIS2024-511420-13-00

Gentofte HospitalCommunity-acquired pneumonia

Target: 460Updated: 2024-07-11

Phase 4

Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study

RecruitingCTIS2024-514900-16-00

Region HovedstadenGram-negative Bacteremia

Start: 2024-07-25Target: 380Updated: 2025-09-12

Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia: A randomized, non-blinded, non-inferiority interventional study

RecruitingCTIS2024-519186-21-01

Hvidovre HospitalStaphylococcus aureus bacteremia

Start: 2025-01-30Target: 264Updated: 2025-11-17